A Phase 2a Randomized Double-blinded Placebo Controlled Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Clinical Activity of BLU-808, a Wild-type KIT Inhibitor, in Participants with Ragweed (Ambrosia artemisiifolia)-induced Allergic Rhinoconjunctivitis.  

To be eligible for this study, you must be:

• 18 years of age or older

• Allergic to ragweed pollen

This is not a complete list of eligibility criteria. The study doctor will review the full entry criteria for this study with you.

Please complete the form below if you are interested in learning more about this study and would like to schedule a phone call with one of our coordinators to discuss further.